1507 related articles for article (PubMed ID: 8899193)
61. Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
Park SJ; Min WS; Yang IH; Kim HJ; Min CK; Eom HS; Kim DW; Han CW; Lee JW; Kim CC
Korean J Intern Med; 2000 Dec; 15(3):224-31. PubMed ID: 11242811
[TBL] [Abstract][Full Text] [Related]
62. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.
Ringdén O; Remberger M; Ruutu T; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Mellander L; Ljungman P; Jacobsen N
Blood; 1999 Apr; 93(7):2196-201. PubMed ID: 10090927
[TBL] [Abstract][Full Text] [Related]
63. Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation.
Frassoni F
Med Oncol Tumor Pharmacother; 1991; 8(3):189-201. PubMed ID: 1803180
[TBL] [Abstract][Full Text] [Related]
64. Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia.
Reiter E; Keil F; Brugger S; Kalhs P; Rabitsch W; Hinterberger W; Fischer G; Rosenmayr A; Haas O; Volc B; Lechner K; Greinix HT
Bone Marrow Transplant; 1997 Jun; 19(12):1191-6. PubMed ID: 9208112
[TBL] [Abstract][Full Text] [Related]
65. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
Dulley FL; Vigorito AC; Aranha FJ; Sturaro D; Ruiz MA; Saboya R; Macedo MC; Da Silva RL; Chamone DA; Mehta J; Bacigalupo A; De Souza CA
Bone Marrow Transplant; 2004 Jan; 33(1):9-13. PubMed ID: 14578930
[TBL] [Abstract][Full Text] [Related]
66. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
[TBL] [Abstract][Full Text] [Related]
67. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA.
Mackinnon S; Barnett L; Bourhis JH; Black P; Heller G; O'Reilly RJ
Blood; 1992 Dec; 80(12):3235-41. PubMed ID: 1467526
[TBL] [Abstract][Full Text] [Related]
68. HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.
Clark RE; Hermans J; Madrigal A; Nachbaur D; Kropshofer G; Gratwohl A; Apperley J; Niederwieser D;
Br J Haematol; 2001 Jul; 114(1):36-41. PubMed ID: 11472342
[TBL] [Abstract][Full Text] [Related]
69. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center.
Abdelkefi A; Ben Othman T; Ladeb S; Torjman L; Hsaïri M; Ben Abdeladhim A
Hematol J; 2003; 4(3):208-13. PubMed ID: 12764353
[TBL] [Abstract][Full Text] [Related]
70. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
Radich JP; Sanders JE; Buckner CD; Martin PJ; Petersen FB; Bensinger W; McDonald GB; Mori M; Schoch G; Hansen JA
J Clin Oncol; 1993 Feb; 11(2):304-13. PubMed ID: 8426208
[TBL] [Abstract][Full Text] [Related]
71. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation.
Min CK; Kim DW; Lee JW; Min WS; Kim CC
Acta Haematol; 2000; 104(4):185-92. PubMed ID: 11279309
[TBL] [Abstract][Full Text] [Related]
72. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
73. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; Boulad F; Castro-Malaspina H; Childs BH; Gillio AP; Kernan NA
Blood; 1995 Aug; 86(4):1261-8. PubMed ID: 7632930
[TBL] [Abstract][Full Text] [Related]
74. Treatment of CML with unrelated donor marrow transplant.
McGlave P
Leuk Lymphoma; 1993; 11 Suppl 1():209-11. PubMed ID: 8251898
[TBL] [Abstract][Full Text] [Related]
75. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases.
McGlave PB; Beatty P; Ash R; Hows JM
Blood; 1990 Apr; 75(8):1728-32. PubMed ID: 2328322
[TBL] [Abstract][Full Text] [Related]
76. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults.
Barker JN; Davies SM; DeFor TE; Burns LJ; McGlave PB; Miller JS; Weisdorf DJ
Br J Haematol; 2002 Jul; 118(1):101-7. PubMed ID: 12100132
[TBL] [Abstract][Full Text] [Related]
77. Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia.
Arai Y; Kondo T; Yamazaki H; Takenaka K; Sugita J; Kobayashi T; Ozawa Y; Uchida N; Iwato K; Kobayashi N; Takahashi Y; Ishiyama K; Fukuda T; Ichinohe T; Atsuta Y; Mori T; Teshima T;
Haematologica; 2016 May; 101(5):644-52. PubMed ID: 26858357
[TBL] [Abstract][Full Text] [Related]
78. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
79. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Dürken M; Graf von Finkenstein F; Erttmann R; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Zander AR
Ann Hematol; 2001 Apr; 80(4):209-15. PubMed ID: 11401086
[TBL] [Abstract][Full Text] [Related]
80. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Aschan J; Carlens S; Hägglund H; Klaesson S; Mattsson J; Remberger M
Clin Transplant; 1999 Dec; 13(6):512-9. PubMed ID: 10617242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
